Lynne E Kelley
CIK 1667584 · View on SEC EDGAR ↗
First SEC filing: April 26, 2019 · Latest: April 26, 2019
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| April 24, 2019 | XFOR | A | 37,170 | — | — | 37,170 Direct | — | Acquired | (price as of 2026-08-19) |
| Oct. 1, 2018 | OCGN | A | 200,000 | — | — | 200,000 Direct | — | Acquired | (price as of 2026-08-19) |
| Oct. 1, 2018 | OCGN | D | 200,000 | — | — | 0 Direct | -100.00% | Disposed | (price as of 2026-08-19) |
| July 31, 2018 | OCGN | A | 200,000 | — | — | 200,000 Direct | — | Acquired | (price as of 2026-08-19) |
| Feb. 2, 2018 | SENS | A | 102,192 | — | — | 102,192 Direct | — | Acquired | (price as of 2026-08-19) |
| Jan. 17, 2017 | SENS | A | 100,000 | — | — | 100,000 Direct | — | Acquired | (price as of 2026-08-19) |
| April 12, 2016 | SENS | A | 334,996 | — | — | 334,996 Direct | — | Acquired | (price as of 2026-08-19) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| April 24, 2019 | XFOR | Stock Option (right to buy) | Common Stock (37,170) | $20.30 | April 24, 2029 | 37,170 | Acquired |
| Oct. 1, 2018 | OCGN | Employee Stock Option (Right to Buy) | Common Stock (200,000) | $0.57 | July 30, 2028 | 200,000 | Acquired |
| Oct. 1, 2018 | OCGN | Employee Stock Option (Right to Buy) | Common Stock (200,000) | $2.21 | July 30, 2028 | 200,000 | Disposed |
| July 31, 2018 | OCGN | Employee Stock Option (Right to Buy) | Common Stock (200,000) | $2.21 | July 30, 2028 | 200,000 | Acquired |
| Feb. 2, 2018 | SENS | Stock Option (right to buy) | Common Stock (102,192) | $2.62 | Feb. 1, 2028 | 102,192 | Acquired |
| Jan. 17, 2017 | SENS | Stock Option (right to buy) | Common Stock (100,000) | $2.74 | Jan. 16, 2027 | 100,000 | Acquired |
| April 12, 2016 | SENS | Stock Option (right to buy) | Common Stock (334,996) | $2.97 | April 12, 2026 | 334,996 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
XFOR
M.D., FACS (7) Former Chief Medical Officer| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2019 | $280,968 | — | — | — | $121,005 | — | $1,604 | $969,951 |
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2016 | $365,000 | — | — | $565,507 | $134,138 | — | — | $1,064,645 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.